By Kelly Stewart
It’s hard to reconcile today’s manufacturing systems with how they operated three scant years ago. The speed with which the industry united to develop, produce, and distribute a novel vaccine is truly astonishing.
Without an unprecedented level of precision and collaboration at the preclinical stage, this wouldn’t have been possible.
In this white paper, we’ll explore the promise of digital manufacturing execution systems (MES) for preclinical process development. We’ll begin with a bird’s-eye overview of the entire drug production lifecycle, and then zero in on what happens at the preclinical stage. In conclusion, we’ll review MES capabilities in the context of preclinical needs and priorities.